SEC Form 4 · accession 0001209191-18-004661
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Azelby
Officer — EVP & Chief Commercial Officer
Period of report
Jan 17, 2018
Accepted (ET)
Jan 19, 2018 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 17, 2018 | M | 2,498 | $25.29 | A | 73,330 | D | |
| Common Stock | Jan 17, 2018 | M | 26,633 | $20.76 | A | 99,963 | D | |
| Common StockF1 | Jan 17, 2018 | S | 21,141 | $68.10 | D | 78,822 | D | |
| Common StockF1 | Jan 17, 2018 | S | 7,990 | $69.95 | D | 70,832 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $25.29 | Jan 17, 2018 | M | 2,498 | D | — | Nov 7, 2026 | Common Stock | 2,498 | 30,836 | D |
| Stock Option (Right to Buy)F3 | $20.76 | Jan 17, 2018 | M | 26,633 | D | — | Feb 6, 2027 | Common Stock | 26,633 | 101,208 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.
- F21/48th of the shares subject to the option vested and became exercisable on December 8, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.
- F31/48th of the shares subject to the option vested and became exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.